Market Access Monthly | Edition #1
Unlock exclusive insights with Market Access Monthly, which delivers MMIT's latest thought leadership straight to your LinkedIn notifications and inbox.
Why Pharma Should Invest in Evidence-Based Physician Education
Evidence-based physician education is an essential element of market access planning for new drugs. This BioPharma Dive article explains how disease state education helps brands develop and communicate their differentiators. Read the full article: https://hubs.ly/Q02PxW6-0 .
When Payers Become Producers: Inside the Private-Labeling Trend
Three payers are now launching manufacturing arms. In Drug Channels, we share new research on how this trend is likely to impact the biosimilar market, PBM contracting, and manufacturers’ market access strategies. Read the full article here: https://hubs.ly/Q02PxVZW0 .
Preparing for the IRA’s Impact on Medicare Plans
Learn how payers are responding to the Inflation Reduction Act and get tips on how to prepare for a future with more restrictive utilization management practices, greater rebating, and a consolidated Medicare landscape. Read the full article here: https://hubs.ly/Q02NVgNc0 .
Coding Chaos: How Pharma Can Help Providers Get Paid
Providers are facing uncertainty about coding requirements for 505(b)(2) generics, plus new drug wastage billing requirements and ongoing NDC/HCPCS crosswalk and unit conversion confusion. Read the full article here: https://hubs.ly/Q02NVgR40 .
?
Tremendous Growth in 2024 Health Insurance Exchange Membership
?The public health insurance exchange segment grew by nearly 3.4 million members last quarter, while Medicaid membership continued to fall. Read the latest enrollment updates for insights into these trends. Read the full article here: https://hubs.ly/Q02NVgSN0 .
Subscribe to the MMIT Market Access Newsletter
Get the latest from MMIT’s leading subject matter experts, and receive the latest posts right in your LinkedIn notifications and inbox.?Click the subscribe button to receive our updates.